Hantz Financial Services Inc. Acquires 49,633 Shares of Roche Holding AG $RHHBY

Hantz Financial Services Inc. grew its holdings in shares of Roche Holding AG (OTCMKTS:RHHBY) by 164.9% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 79,732 shares of the company’s stock after buying an additional 49,633 shares during the period. Hantz Financial Services Inc.’s holdings in Roche were worth $4,112,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of RHHBY. Oakworth Capital Inc. bought a new stake in shares of Roche during the 3rd quarter valued at $57,000. Sentinel Trust Co. LBA bought a new stake in shares of Roche during the 3rd quarter valued at $878,000. Altrius Capital Management Inc boosted its holdings in shares of Roche by 4.0% during the 3rd quarter. Altrius Capital Management Inc now owns 198,278 shares of the company’s stock valued at $8,290,000 after buying an additional 7,659 shares in the last quarter. S&CO Inc. boosted its holdings in shares of Roche by 1.9% during the 3rd quarter. S&CO Inc. now owns 52,154 shares of the company’s stock valued at $2,129,000 after buying an additional 955 shares in the last quarter. Finally, PNC Financial Services Group Inc. boosted its holdings in shares of Roche by 23.0% during the 3rd quarter. PNC Financial Services Group Inc. now owns 18,799 shares of the company’s stock valued at $786,000 after buying an additional 3,513 shares in the last quarter.

Wall Street Analysts Forecast Growth

RHHBY has been the topic of a number of research reports. Citigroup began coverage on shares of Roche in a report on Tuesday, January 27th. They set a “buy” rating on the stock. Argus upgraded shares of Roche from a “hold” rating to a “buy” rating in a research note on Monday, April 6th. Wolfe Research reiterated an “outperform” rating on shares of Roche in a research note on Thursday, February 26th. Morgan Stanley upgraded shares of Roche from an “underweight” rating to an “equal weight” rating and set a $46.00 price target on the stock in a research note on Friday, April 24th. Finally, TD Cowen reiterated a “hold” rating on shares of Roche in a research note on Tuesday, February 10th. Five analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $51.50.

Roche Stock Performance

Shares of Roche stock opened at $53.34 on Tuesday. The firm’s 50-day moving average is $50.52 and its 200 day moving average is $51.89. Roche Holding AG has a 1 year low of $37.51 and a 1 year high of $60.85. The company has a current ratio of 1.38, a quick ratio of 1.12 and a debt-to-equity ratio of 0.72.

Roche Profile

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.